Bioflor Mechanism of Action

Pharmacotherapeutic classification: ANTI-DIARRHOEA, Replacement flora (A: digestive system and metabolism).
Pharmacology: Pharmacodynamics: Saccharomyces boulardii (Sb) CNCM I-745 is an intestinal replacement flora which acts as antidiarrhoeal microorganisms in the digestive tract. Pharmacodynamics of Saccharomyces boulardii CNCM I-745, live probiotic yeast, have been established on various models by in vitro and in vivo, animal, and human studies which demonstrated it acts at 3 levels: Luminal action: Sb may interfere with pathogen toxins, preserve cellular physiology, interfere with pathogens attachment (anti-toxinic effect against C. difficile, cholera, E. coli through preservation of tight junctions, adhesion of the bacteria to Sb enabling to stop the bacterial invasion), interact with normal microbiota or assist in re-establishing short chain fatty acid levels.
Trophic action: Sb reduces mucositis, restores fluid transport pathways, stimulates protein and energy production or act through a trophic effect by releasing spermine and spermidine or other brush border enzymes that aid in the maturation of enterocytes. Immune response: Sb increases the IgA levels in the intestine.
Mucosal action - anti-inflammatory effect: Sb may interfere with NF-κB mediated signal transduction pathways which stimulate pro-inflammatory cytokine production.
In lyophilized form, S. boulardii CNCM I-745 survives gastric acid and bile and can be detected alive throughout the entire digestive system (if ingested daily in freeze-dried form). S. boulardii CNCM I-745 is also resistant to proteolysis. So it acts all along the intestine.
Pharmacokinetics: Saccharomyces boulardii CNCM I-745 is not absorbed. After repeated oral doses, it transits in the digestive tract without colonizing it, rapidly attaining significant intestinal concentrations which are maintained at a constant level throughout the administration period. Saccharomyces boulardii CNCM I-745 is no longer present in the stools 2 to 5 days after discontinuation of treatment.
After 3 days of administration, a stable concentration in the intestinal content is reached. Within 1 week after stopping the administration, S. boulardii CNCM I-745 becomes undetectable.
Saccharomyces boulardii CNCM I-745 is not absorbed from the intestinal tract. The number of living yeast cells in faeces decreases fast after discontinued treatment, and 5 days after discontinuation the level hereof is below measurable level.